Particularly, new agents targeting TSLP or TSLPR such as ASP7266 (a novel recombinant monoclonal antibody against TSLPR) and BP79 (a small- molecular inhibitor against TSLP-TSLPR), which crucial role is demonstrated by overwhelming basic studies are given great expectations in treating asthma combined with AD, although there is no clinical trial supporting the efficacy of TSLP-targeting drugs against AD at present. This evidence concerns the gene TSLP and asthma.